AI assistant
10x Genomics, Inc. — Director's Dealing 2020
Jul 3, 2020
31830_dirs_2020-07-02_62aca7fc-39c6-4f92-83b3-1d74216e22bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-07-01
Reporting Person: McAnear Justin J. (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-07-01 | Class A Common Stock | M | 10000 | $5.04 | Acquired | 10000 | Direct |
| 2020-07-01 | Class A Common Stock | S | 5121 | $87.1781 | Disposed | 4879 | Direct |
| 2020-07-01 | Class A Common Stock | S | 4779 | $88.03 | Disposed | 100 | Direct |
| 2020-07-01 | Class A Common Stock | S | 100 | $88.63 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-07-01 | Stock Option (right to buy) | $5.04 | M | 10000 | Disposed | 2028-11-02 | Class A Common Stock (10000) | Direct |
Footnotes
F1: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $86.60 to $87.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $87.60 to $88.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This option, originally for 600,000 shares, of which 50,000 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.